

**Mr Mark Reid**

14 September 2018

**Supplementary Submission**

Response to QVFA Supplementary submission 16.8

---

Ms Lyn Beverley  
Committee Secretary  
Senate Foreign Affairs, Defence and Trade references Committee  
PO Box 6100 parliament House  
Canberra ACT 2600

Dear Lyn,

**Re Senate Inquiry – Use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force. – Supplementary Submission made by Major McCarthy (retired)**

I understand Major McCarthy (retired) has made another supplementary submission in relation to my oral testimony presented to the Committee on the 30<sup>th</sup> August 2018. The date of Major McCarthy (retired) new submission is the 13<sup>th</sup> September 2018 after he made the tweet (copied below on the 11<sup>th</sup> September 2018).

Allegation of misleading the Committee about “Cooperative Research and Development Agreements”:

- To my knowledge, the US Federal Technology Transfer Act of 1986 ((p.l. 99-502) enables US government departments to form cooperative research and development agreements (CRADA) with commercial parties.
- In kind (but not direct) funding is permitted to support CRADA partners but the government co-development partner cannot give money directly to a CRADA partner.
- Therefore, my oral testimony to Senator O’Sullivan stands. The US government cannot pay money to 60P “to do this work” under the US Federal Technology Transfer Act of 1986.
- 60 degrees Pharmaceuticals LLC and the US Army Medical Materiel Development Activity are CRADA partners as evidenced by the CRADA obtained by Dr. Remington Nevin under a Freedom of Information (FOI) request.
- I believe a copy of this 60P-USAMMDA CRADA has been submitted to the Committee by Major McCarthy (retired) on the 6<sup>th</sup> September 2018.
- As this is a Sponsor question, I believe it appropriate to refer the Committee to any relevant testimony from Dr. Dow.
- Incidentally, a CRADA between Bristol Myers Squibb and the US National Cancer Institute (NCI) was agreed in the 1980s and led to the commercialisation of Taxol® (paclitaxel) for ovarian and breast cancer. Over > 1 million cancer patients have been treated with this drug developed under this CRADA including Australian citizens as Taxol® was approved by the Australian TGA in September 2004.
- <https://techtransfer.cancer.gov/aboutttc/successstories/taxol>
- <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02667-3&d=201809141016933>

Replying to [@mefloq\\_vets\\_UK](#) [@JaneCQuinn1](#) and 10 others

It's simple. [@reid99mark](#) has deliberately misled [@AuSenate](#) . Lock him up please. He cares not for our laws and he is an external threat to the country. [#TafenoquineRC](#) [#Mefloquine@AmandaRishworth](#) [@c\\_otoole@AdamBandtpic.twitter.com/SQ6BrGL9W0](#)

	
<p><b>Senator O'SULLIVAN:</b> <i>I just want to try and get these relationship lines, because they're important, as you'd appreciate, as we give weight to the various testimonies that are provided. Is it the case that the US military, using public funding, socialised funding, paid 60 Degrees to embark on this journey?</i></p>	<p><i>"Ongoing U.S. Army support - \$18+ million for development program."</i></p>
<p><b>Mr Reid :</b> <i>No. They're not allowed to.</i></p>	
<p>~ Hansard, 30 August 2018</p>	<p>~ 60 Degrees Pharma website</p>

2 replies 5 retweets 4 likes

2  
5  
5  
4  
4